|
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
Sep 2024 |
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
Oct 2024 |
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
|
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Family reflections: pediatric aplastic anemia research; a parent perspective |
Oct 2024 |
Pediatric Research |
Aplastic Anemia, Pediatric |
|
Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten |
Oct 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Oct 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
